Wallace Lovell Akerley III MD

Oncology•Salt Lake City, UT

Hematologic Oncology, Thoracic Cancer

Professor of Medicine, University Utah

Join to View Full Profile

1950 Circle of HopeClinic 1aSalt Lake City, UT 84112
Phone+1 801-585-0100
Fax+1 801-585-7902

Education & Training

Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Hematology and Medical Oncology, 1985 - 1989
University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 1984 - 1985
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 1981 - 1984
The Warren Alpert Medical School of Brown UniversityClass of 1981

Certifications & Licensure

CA State Medical License 1982 - Present
UT State Medical License 2002 - 2026
RI State Medical License 1989 - 2000
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

S0119: Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2002 Jan 01
Completed
Phase 2
Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer Start of enrollment: 2007 Aug 01
Completed
Phase 2
A Phase 2 Study of Tarceva for Untreated, Good Prognosis Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2004 Jun 01
Completed
Phase 2
Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer Start of enrollment: 2013 Dec 02
Completed
Phase 1
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
ACTIVE_NOT_RECRUITING
PHASE3
Tumor Treating Fields for Locally Advanced NSCLC Start of enrollment: 2024 Apr 04
RECRUITING
PHASE1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Association between physical activity, performance scores, and clinical trial enrollment in cancer survivors.
Kelsey E Maslana, Ryan D Burns, Paul A Estabrooks, Mary C Playdon, Janet M Shaw
BMC Cancer. 2025-08-26
1 citations
Thymomas and Thymic Carcinomas, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.
Gregory J Riely, Douglas E Wood, Billy W Loo, Dara L Aisner, Wallace Akerley
Journal of the National Comprehensive Cancer Network. 2025-06-01
BRAF-Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor Signaling.
Melanie Angelina Dacheux, Meng-Jung Wu, Michael T Scherzer, Monique Nillson, Brandon Murphy
Biorxiv. 2025-05-09

Press Mentions

'I'd Been so Healthy': Radon Gas Continues to Causes Illnesses in Utah HomesOctober 27th, 2024
Do Low-Grade irAEs with Atezolizumab Predict Survival in Stage IV NSCLC?March 9th, 2023
Biodesix Presents New Data from the INSIGHT Study at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual MeetingNovember 10th, 2022
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Wallace Lovell Akerley III MD

Dr. Akerley is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.